Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018

Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018


  • Products Id :- GMDHC10770IDB
  • |
  • Pages: 113
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H2 2018, provides an overview of the Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 4

Neuromyelitis Optica (Devic's Syndrome)-Overview 5

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics Development 6

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics Assessment 14

Neuromyelitis Optica (Devic's Syndrome)-Companies Involved in Therapeutics Development 22

Neuromyelitis Optica (Devic's Syndrome)-Drug Profiles 28

Neuromyelitis Optica (Devic's Syndrome)-Dormant Projects 99

Neuromyelitis Optica (Devic's Syndrome)-Discontinued Products 100

Neuromyelitis Optica (Devic's Syndrome)-Product Development Milestones 101

Appendix 109

List of Figures

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Abide Therapeutics Inc, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Acer Therapeutics Inc, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Alexion Pharmaceuticals Inc, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Biogen Inc, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Bionure Farma SL, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Boston Pharmaceuticals Inc, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Endece LLC, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by HanAll Biopharma Co Ltd, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by LFB SA, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Tolerion Inc, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Vicore Pharma AB, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Dormant Projects, H2 2018

Neuromyelitis Optica (Devic's Syndrome)-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Abide Therapeutics Inc

Acer Therapeutics Inc

Alexion Pharmaceuticals Inc

Biogen Inc

Bionure Farma SL

Boston Pharmaceuticals Inc

Chugai Pharmaceutical Co Ltd

Endece LLC

HanAll Biopharma Co Ltd

LFB SA

Tolerion Inc

Vicore Pharma AB

Neuromyelitis Optica (Devic's Syndrome) Therapeutic Products under Development, Key Players in Neuromyelitis Optica (Devic's Syndrome) Therapeutics, Neuromyelitis Optica (Devic's Syndrome) Pipeline Overview, Neuromyelitis Optica (Devic's Syndrome) Pipeline, Neuromyelitis Optica (Devic's Syndrome) Pipeline Assessment

select a license
Single User License
USD 2000 INR 142680
Site License
USD 4000 INR 285360
Corporate User License
USD 6000 INR 428040

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com